Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Today tags : Trial save search
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
KRON | $0.9644 1.52% 1.49% 880K
|
Health Technology
| Email alert
Add to watchlist
kb-0742 update meeting trial
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
NVCR | $12.35 2.45% 2.39% 1.1M
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
lung asco cancer cell for trial results
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
bxcl701 keytruda presentation asco pancreatic for meeting trial therapeutics
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Published: 2024-04-24 (Crawled : 14:00) - biospace.com/
KRBP | $2.64 -90.21% 360
|
Health Technology
| Email alert
Add to watchlist
first favorable biopharma trial
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K
|
Professional, Scientific, and T...
|
| O: -0.29%
H: 0.0%
C: 0.0%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CYTO | $1.495 -5.38% -5.69% 3M
|
Manufacturing
|
| O: -0.63%
H: 0.0%
C: 0.0%
positive publication bentrio trial therapeutics results
Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
KTTA | $7.09 -1.19% 910
|
| Email alert
Add to watchlist
pas-004 first trial therapeutics
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
NVNO | $5.27 -4.18% -4.36% 100K
|
Manufacturing
|
| O: 8.82%
H: 0.0%
C: 0.0%
symposium positive topline trial today
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Published: 2024-04-24 (Crawled : 11:00) - hancockjaffe.com
NVNO | $5.27 -4.18% -4.36% 100K
|
Manufacturing
|
| O: 8.82%
H: 0.0%
C: 0.0%
venovalve symposium positive topline trial today
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.